HTG Molecular Diagnostics (HTGM) Reports Q4 Loss of $0.76/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results
March 23, 2017 4:03 PM EDTTUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the fourth quarter and year ended December 31, 2016.
Recent Accomplishments & Highlights:
Signed a development, manufacturing and commercialization agreement with a wholly owned affiliate of QIAGEN, N.V.  QIAGEN North American Holdings also made a minority investment in HTGs common stock  Completed technical feasibility assay for QIAGEN GeneReader next-generation sequencing platformObtained CE marking for the HTG EdgeSeq... More